BSI-201 (iniparib)

DRUG2 trials

Sponsors

Sanofi

Conditions

TumorsUterine Carcinosarcoma

Phase 1

Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

CompletedNCT00298675

Start: 2006-03-31End: 2011-05-31Updated: 2012-08-02

Phase 2

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

CompletedNCT00687687

SanofiUterine Carcinosarcoma

Start: 2008-05-31End: 2011-12-31Updated: 2012-08-07